Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cholecystectomy & appendectomy cases in Alaska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (255 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 411 | 2% |
| 2020 | 2 | 341 | 2% |
| 2021 | 3 | 407 | 2% |
| 2022 | 3 | 343 | 3% |
| 2023 | 2 | 363 | 3% |
| 2024 | 3 | 396 | 3% |
| 2025 from claims | – | 453 366–531 | 3% |
| 2026 forecast | – | 462 362–580 | 3% |
| 2027 forecast | – | 470 349–621 | 3% |
| 2028 forecast | – | 479 339–661 | 3% |
| 2029 forecast | – | 487 331–699 | 3% |
| 2030 forecast | – | 496 325–736 | 3% |
The highest-volume laparoscopic cases; identifies every active general surgeon. Professional codes (what the surgeon bills): CPT 47562, 47563, 44970, 47600; the hospital bills MS-DRG 417, 418, 419, 338, 339, 340, 397, 398, 399.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Alaska; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 45% inpatient hospital, 55% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~460 | ~210 | ~250 |
| 2027 · ~470 | ~220 | ~250 |
| 2028 · ~480 | ~220 | ~260 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 47% (45% in 2025), hospital outpatient about 53% (55% in 2025).
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| California | 221 | 11,459−2.6%/yr | −2.6%/yr | 3.5 | 2% | 12,600 in 2030+1.6%/yr |
| Arizona | 74 | 3,384−3.1%/yr | −3.1%/yr | 4.7 | 5% | 3,490 in 2030+0.5%/yr |
| Washington | 31 | 2,636−5.6%/yr | −5.6%/yr | 3.5 | 2% | 2,630 in 20300%/yr |
| Colorado | 18 | 1,923−3.3%/yr | −3.3%/yr | 4.1 | 3% | 2,250 in 2030+2.6%/yr |
| Oregon | 12 | 1,552−4.6%/yr | −4.6%/yr | 3.8 | 1% | 1,830 in 2030+2.8%/yr |
| Nevada | 21 | 1,144−2.4%/yr | −2.4%/yr | 4.1 | 0% | 1,330 in 2030+2.6%/yr |
| Utah | 13 | 952−6.8%/yr | −6.8%/yr | 4.5 | 2% | 1,140 in 2030+3%/yr |
| Idaho | 14 | 858−2.1%/yr | −2.1%/yr | 4.3 | 0% | 1,150 in 2030+5%/yr |
| New Mexico | 9 | 736−6.4%/yr | −6.4%/yr | 3.3 | 0% | 870 in 2030+2.8%/yr |
| Montana | 9 | 685−6%/yr | −6%/yr | 3.7 | 2% | 740 in 2030+1.2%/yr |
| Wyoming | 4 | 353−6.8%/yr | −6.8%/yr | 3.3 | 6% | 390 in 2030+1.8%/yr |
| Hawaii | 2 | 277−3.2%/yr | −3.2%/yr | 2.2 | 0% | 360 in 2030+4.7%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Hernia repair | 8 | 607+4.7%/yr | +4.7%/yr | 5.10.8× | 8% | 750 in 2030+3.5%/yr |
| Colorectal resection | 0 | 161−1.8%/yr | −1.8%/yr | 1.30.9× | 0% | 170 in 2030+1.2%/yr |
Cholecystectomy & appendectomy in every state, and its device makers · Every procedure market in Alaska · Every state · Compare with California
Johnson & Johnson MedTech leads with 81% of company spending on these surgeons in 2025, +22 pts on 2024.
In 2025, 3 companies reported engagement with Alaska’s surgeons worth $2,213 in consulting, speaking, meals and travel tied to these products, about $738 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 33 clearances and approvals in the category, 2 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.